Patent intelligence · WO
WO 2009076388
CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE
CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE
Patent details — WO 2009076388
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Jun 18, 2009
- Expiration
- Jun 13, 2029
- Applicant
- BRACCO INT BV [NL]
- CPC classes
- A61K 49/ 22 A I, A61K/49227, A61P 35/ 00 A I, A61P/3500
Quick answer
WO 2009076388 (CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE) is held by BRACCO INT BV [NL]. Status: granted. Granted Jun 18, 2009. Expires Jun 13, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BRACCO INT BV [NL]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 49/ 22 A I, A61K/49227, A61P 35/ 00 A I, A61P/3500
More from BRACCO INT BV [NL]
Related pharmaceutical patents in our USPTO index.
-
IL 172160
Method for non-invasive quantification of perfusion in a tissue
granted -
EP 2117603
TARGETING UND THERAPEUTISCHE VERBINDUNGEN UND GASGEFÜLLTE MIKROVESIKEL MIT DIESEN VERBINDUNGEN
granted -
CA 2670932
DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE
granted -
US 2008107607
TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
granted -
US 2008063603
ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM
granted -
CA 2631716
CONJUGUES VECTEUR DE CIBLAGE-PHOSPHOLIPIDES
granted -
US 2007128117
Ultrasound contrast agents and process for the preparation thereof
granted
Frequently asked questions
What is US patent 2009076388?
WO 2009076388 (CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE) is held by BRACCO INT BV [NL]. Status: granted. Granted Jun 18, 2009. Expires Jun 13, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2009076388?
BRACCO INT BV [NL] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2009076388 expire?
Our index shows an expiration date of Jun 13, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.